Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript

Cyclacel Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-6.23, expectations were $-6.35.

Keep Reading →